ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Grant, contract Awards Held Up By Impasse On Appropriations

October 14, 1977

Medicare: Clinton Budget Revives Proposal To End Physician Drug Markup

February 6, 1998

In Brief: Cancer Act Extension, Training Bill Breezing Through Congress; Army Causes Ft. Detrick Flap

July 5, 1974

Hood’s ISB Gets $5 Million From Merck, Hires Scientists.

September 1, 2000

CCRU, CCSP Projects Described; Plans Listed for DRCCA Applications Branch

November 11, 1983

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011